Hikma Pharmaceuticals signs deal with Theravance for Vibativ

Hikma Pharmaceuticals has signed an exclusive commercialisation agreement with Theravance for Vibativ in the Middle East and North Africa (MENA).Vibativ is a bactericidal, once-daily antibiotic for bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a dangerous skin and soft tissue infection pathogen, causing serious infections in both hospitalised patients and patients in the MENA region.Under the agreement, Hikma will have the exclusive rights to register, market and distribute Vibativ in 16 countries across MENA. Hikma said the agreement will leverage its local presence in MENA, with over 1,600 sales and marketing representatives across the region.Said Darwazah, Hikma's Chief Executive, said: "We are pleased to be partnering with Theravance to bring Vibativ to patients in the MENA region. Vibativ is an excellent product that will enhance our broad portfolio of anti-infective products and offers a good market opportunity. Strengthening our product portfolio through partnerships such as this continues to be a key component of our MENA growth strategy."RD